VistaGen Therapeutics (VTGN) Stock Forecast & Price Target

Compare

1,184 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VTGN Analyst Ratings

Hold

0 Buy

5 Hold

0 Sell

Based on 5 analysts giving stock ratings to

VistaGen

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VTGN Stock 12 Month Forecast

Average Price Target

$0.97

▲(36.62% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $0.97 with a high forecast of $1.00 and a low forecast of $0.90. The average price target represents a 36.62% change from the last price of $0.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.43,4.166153846153846,3.902307692307692,3.638461538461538,3.3746153846153844,3.1107692307692307,2.8469230769230767,2.5830769230769226,2.319230769230769,2.0553846153846154,1.7915384615384613,1.5276923076923072,1.2638461538461536,{"y":1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.43,4.163846153846154,3.8976923076923073,3.6315384615384616,3.365384615384615,3.0992307692307692,2.833076923076923,2.566923076923077,2.3007692307692307,2.0346153846153845,1.7684615384615383,1.5023076923076921,1.2361538461538464,{"y":0.97,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.43,4.158461538461538,3.8869230769230767,3.615384615384615,3.3438461538461537,3.0723076923076924,2.8007692307692307,2.529230769230769,2.2576923076923077,1.9861538461538464,1.7146153846153847,1.443076923076923,1.1715384615384616,{"y":0.9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1.00

Average Price Target$0.97

Lowest Price Target$0.90

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

Hold

―

Downgraded

12/18/25

Vistagen downgraded to Market Perform from Outperform at William BlairVistagen downgraded to Market Perform from Outperform at William Blair

Andrew Tsai

Jefferies

$15→$0.9

Hold

26.76%

Upside

Downgraded

12/17/25

Vistagen downgraded to Hold from Buy at JefferiesVistagen downgraded to Hold from Buy at Jefferies

Paul Matteis

Stifel Nicolaus

$12→$1

Hold

40.85%

Upside

Downgraded

12/17/25

Vistagen downgraded to Hold from Buy at StifelVistagen downgraded to Hold from Buy at Stifel

Elemer Piros

Lucid Capital

$19→$1

Hold

40.85%

Upside

Downgraded

12/17/25

Vistagen downgraded to Neutral from Buy at Lucid CapitalVistagen downgraded to Neutral from Buy at Lucid Capital

Jason McCarthy

Maxim Group

Hold

―

Downgraded

12/17/25

Vistagen downgraded to Hold from Buy at MaximVistagen downgraded to Hold from Buy at Maxim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

Hold

―

Downgraded

12/18/25

Vistagen downgraded to Market Perform from Outperform at William BlairVistagen downgraded to Market Perform from Outperform at William Blair

Andrew Tsai

Jefferies

$15→$0.9

Hold

26.76%

Upside

Downgraded

12/17/25

Vistagen downgraded to Hold from Buy at JefferiesVistagen downgraded to Hold from Buy at Jefferies

Paul Matteis

Stifel Nicolaus

$12→$1

Hold

40.85%

Upside

Downgraded

12/17/25

Vistagen downgraded to Hold from Buy at StifelVistagen downgraded to Hold from Buy at Stifel

Elemer Piros

Lucid Capital

$19→$1

Hold

40.85%

Upside

Downgraded

12/17/25

Vistagen downgraded to Neutral from Buy at Lucid CapitalVistagen downgraded to Neutral from Buy at Lucid Capital

Jason McCarthy

Maxim Group

Hold

―

Downgraded

12/17/25

Vistagen downgraded to Hold from Buy at MaximVistagen downgraded to Hold from Buy at Maxim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

VTGN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VTGN has received 6 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. VTGN average Analyst price target in the past 3 months is 0.97.

Each month's total comprises the sum of three months' worth of ratings.

VTGN Financial Forecast

VTGN Earnings Forecast

Next quarter’s earnings estimate for VTGN is -$0.49 with a range of -$0.54 to -$0.42. The previous quarter’s EPS was -$0.54. VTGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VTGN has Performed in-line its overall industry.

VTGN Sales Forecast

Next quarter’s sales forecast for VTGN is $364.00K with a range of $258.00K to $535.00K. The previous quarter’s sales results were $258.00K. VTGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VTGN has Performed in-line its overall industry.

VTGN Stock Forecast FAQ

What is VTGN’s average 12-month price target, according to analysts?

Based on analyst ratings, VistaGen Therapeutics’s 12-month average price target is 0.97.

What is VTGN’s upside potential, based on the analysts’ average price target?

VistaGen Therapeutics has 36.62% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VTGN a Buy, Sell or Hold?

VistaGen Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 5 hold ratings and 0 sell ratings.

What is VistaGen Therapeutics’s price target?

The average price target for VistaGen Therapeutics is 0.97. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1.00 ,the lowest forecast is $0.90. The average price target represents 36.62% Increase from the current price of $0.71.

What do analysts say about VistaGen Therapeutics?

VistaGen Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of VTGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

VistaGen Therapeutics (VTGN) Stock Forecast & Price Target

VTGN Analyst Ratings

VTGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

VTGN Analyst Recommendation Trends

VTGN Financial Forecast

VTGN Earnings Forecast

VTGN Sales Forecast

VTGN Stock Forecast FAQ

Detailed List of Analyst Forecasts